Patient characteristics at ATTIRE trial entry
NAFLD, end-stage liver disease
NONALCOHOLIC FATTY LIVER DISEASE, VIRUS, HEPATITIS C
A total of 397 of 777 (51%) patients received standard care and were subjected to parenclitic analysis. During the 6-month follow-up period, 119 (30%) of these patients died. Table Demographic and baseline clinical variables in the study populationThe bold entries indicate HCV, hepatitis C virus; IQR, interquartile range; MELD, model for end-stage liver disease; NAFLD, nonalcoholic fatty liver disease.